- Home
- BZAI vs TVRD Comparison
BZAI vs TVRD Comparison
Compare BZAI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BZAI | TVRD |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 34.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BZAI | TVRD |
|---|---|---|
| Price | $1.09 | $3.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.50 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 1.9M | 37.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,317.12 | N/A |
| Revenue Next Year | $250.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.50 |
| 52 Week High | $6.76 | $43.65 |
Technical Indicators
Market Signals| Indicator | BZAI | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 47.01 |
| Support Level | $1.04 | $3.81 |
| Resistance Level | $1.57 | $4.45 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 28.89 | 38.12 |
Price Performance
Historical ComparisonAbout BZAI Blaize Holdings Inc.
Blaize Holdings Inc provides a customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.